RxDoctor Payments Data

Chad Hamilton, MD

Gynecologic Oncology · Annandale, VANPI 1699733808

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $149,708 of the $242,115 with a category attached, or 61.8%. GSK accounts for 60.4% of it on its own, with 28 other manufacturers making up the rest. Among gynecologic oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$242,115in general payments, 2019–2025

Across 249 payments — averaging $972.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$146K
  • Tesaro, Inc.$37K
  • AbbVie$29K
  • AstraZeneca$17K
  • Merck$7K
  • Pfizer$2K
  • plus $4K from 23 others
$1,243in research payments, 2019–2025

Across 2 payments — averaging $621.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1K

What the payments were for

  • Consulting fees$75,31831%
  • Speaking & faculty fees$149,70862%
  • Travel & lodging$10,2684%
  • Food & beverage$6,4693%
  • Education$3530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$242,115 in reported general payments places this provider in the 95th percentile of 47 gynecologic oncology providers in Virginia.

See all gynecologic oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$33,872
Medicare patients
55
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone11$66

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →